In this study, we focused on the combination of Nutlin-3 with CDDP (cis-diamminedichloroplatinum(II); cisplatin), a well-known activator of the p53 pathway, in a series of non-small cell lung cancer (NSCLC) cell lines with different p53 background (Figure 1). The gene discussed is TP53; the disease is non-small cell lung carcinoma.